proctosigmoiditis

proctosigmoiditis

 [prok″to-sig″moi-di´tis]
inflammation of the rectum and sigmoid colon.

proc·to·sig·moi·di·tis

(prok'tō-sig'moy-dī'tis),
Inflammation of the sigmoid colon and rectum.
[procto- + sigmoid + G. -itis, inflammation]

proc·to·sig·moi·di·tis

(prok'tō-sig'moyd-ī'tis)
Inflammation of the sigmoid colon and rectum.
[procto- + sigmoid + G. -itis, inflammation]
References in periodicals archive ?
Innovation Pharmaceuticals has executed a license agreement with Alfasigma to develop and commercialize locally-administered Brilacidin on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. The company will receive from Alfasigma an initial payment, plus be eligible for additional payments based on certain milestones, totaling over $24M, and receive a 6 percent royalty,based on the successful marketing of Brilacidin for UP/UPS.
Grade 1: Mild symptoms of enteritis, proctosigmoiditis, cystitis, etc., that subsides with conservative treatment.
Patel, "Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension," Digestive Diseases and Sciences, vol.
Lee and colleagues [44] found right-sided colitis and proctosigmoiditis varied in colonoscopic appearance.
(18) and no difference in T-score was observed between proctosigmoiditis and extensive colitis.
Biopharmaceutical company Cellceutix Corporation (OtherOTC:CTIX) disclosed on Tuesday the completion of enrolment under the second cohort of the Phase 2 open label Proof-of-Concept trial evaluating Brilacidin for treating mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease.
Wu, "A rare cause of ischemic proctosigmoiditis: idiopathic myointimal hyperplasia of mesenteric veins," Endoscopy, vol.
Patients with proctitis and proctosigmoiditis have little or no increased risk of cancer compared with the general population; therefore, the usual screening program for colorectal cancer for the general population may suffice for these patients.
Control Remission Active UC UC Mean age (years) 44.4 40.4 39.4 Gender Female 19 9 15 Male 12 11 11 Clinical course Initially active and then inactive 10 6 Mild intermittent activity: <2 10 19 relapse/year Intense intermittent activity: >2 0 0 relapse/year Continuous activity (refractory to 0 1 treatment) Extension Pancolitis (n) 9 16 Left-sided colitis (n) 5 4 Proctosigmoiditis (n) 6 6 Extraintestinal manifestation Present (n) 8 9 Absent (n) 12 15 Treatment Monotherapy with 5-aminosalicylates 12 7 (n) Combined therapy (n) 6 13 Response to treatment Present (n) 17 19 Absent (n) 3 7
(14.) Martin P, Manley PN, Depew WT, et al: Isotretinoin-associated proctosigmoiditis. Gastroenterology 1987;93:606-9.
Thirteen patients with proctosigmoiditis, 20 patients with left sided colitis, and 9 patients with pancolitis were enrolled in UC group.